Genelux Investor Presentation Deck
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections, about Genelux Corporation ("Genelux," the "Company," "we," "us" or
"our") that are based on the beliefs and assumptions of our management team, and on information currently available to such management team. These forward-looking
statements include, but are not limited to, statements concerning: Olvi-Vec's potential utility and our plans and expectations for Olvi-Vec across various designs and
indications; our expectations regarding the field of oncolytic viral immunotherapy; Olvi-Vec's potential to provide utility across multiple tumor types, and our expectations
regarding our Phase 3 trial; our clinical trial strategy and design; our expectations regarding (i) the timing of our Phase 2 and Phase 3 clinical trials and (ii) our intellectual
property rights under the Newsoara license agreement; our planned investments to meet worldwide clinical trial demand and facilitate our U.S. commercial launch; the
commercial market opportunity for Olvi-Vec in the United States; our various commercial strategies for self-launching Olvi-Vec for ovarian cancer in the United States,
including expected milestones related to clinical trials and commercial partnerships and collaborations; and our expectations regarding our cash operating runway. These
forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact,
contained in this presentation, including statements regarding future events, future financial performance, business strategy and plans, and objectives of ours for future
operations, are forward-looking statements.
Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are
only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth under the heading "Risk Factors” in our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2023, and in our other filings with the SEC, which may cause our actual results, levels of activity, performance or achievements
of and those of our industry to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking
statements. You should not place undue reliance on any forward-looking statement. Forward-looking statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "contemplate,"
"continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would," or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain these identifying words. You should not put undue reliance on any forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved, if at all. Except as required by law, Genelux does not undertake any obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future developments or otherwise.
Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the
trademarks and tradenames referred to in this presentation appear without the Ⓡ and ™ symbols, but those references are not intended to indicate, in any way, that we will
not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.
This presentation discusses a product candidate that is under clinical study and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No
representation is made as to the safety or effectiveness of this product candidate for the use for which it is being studied.View entire presentation